Toxicity Signals Associated with Secukinumab: A Pharmacovigilance Study Based on The United States Food And Drug Administration Adverse Event Reporting System Database

Br J Clin Pharmacol. 2022 doi: 10.1111/bcp.15535

This study explored the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab with hypersensitivity identified as the most common toxicity.

Beyond the prevalence of hypersensitivity, there were multiple other common AEs. IBD, genital candidiasis, dermatitis psoriasiform, and anosmia were the PTs with the highest IC025 in each type. These toxicities occurred predominantly in the first month following treatment initiation. This investigation therefore contributes to a further understanding of the safety of secukinumab as well as assisting in the clinical understanding of how clinicians can better care for their patients.